Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2023 Sep 14

PMID 37706062

Authors

Anna Felis-Giemza

Magdalena Massalska

Leszek Roszkowski

Katarzyna Romanowska-Prochnicka

Marzena Ciechomska

Affiliations

Soon will be listed here.

Abstract

It is well known that fatigue is a highly disabling symptom commonly observed in inflammatory rheumatic diseases (IRDs). Fatigue is strongly associated with a poor quality of life and seems to be an independent predictor of job loss and disability in patients with different rheumatic diseases. Although the pathogenesis of fatigue remains unclear, indirect data suggest the cooperation of the immune system, the central and autonomic nervous system, and the neuroendocrine system in the induction and sustainment of fatigue in chronic diseases. Fatigue does not correspond with disease activity and its mechanism in IRDs. It is suggested that it may change over time and vary between individuals. Abnormal production of pro-inflammatory cytokines such as interleukin-6 (IL-6), interferons (IFNs), granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF, IL-15, IL-17 play a role in both IRDs and subsequent fatigue development. Some of these cytokines such as IL-6, IFNs, GM-CSF, and common gamma-chain cytokines (IL-15, IL-2, and IL-7) activate the Janus Kinases (JAKs) family of intracellular tyrosine kinases. Therapy blocking JAKs (JAK inhibitors - JAKi) has been recently proven to be an effective approach for IRDs treatment, more efficient in pain reduction than anti-TNF. Therefore, the administration of JAKi to IRDs patients experiencing fatigue may find rational implications as a therapeutic modulator not only of disease inflammatory symptoms but also fatigue with its components like pain and neuropsychiatric features as well. In this review, we demonstrate the latest information on the mechanisms of fatigue in rheumatic diseases and the potential effect of JAKi on fatigue reduction.

Citing Articles

The steroid-sparing effect of JAK inhibitors across multiple patient populations.

Conigliaro P, Minerba C, Vendola A, Fiannacca L, Triggianese P, Kroegler B Front Immunol. 2024; 15:1376476.

PMID: 38680499 PMC: 11045928. DOI: 10.3389/fimmu.2024.1376476.

References

Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W . The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009; 7:25. PMC: 2674445. DOI: 10.1186/1477-7525-7-25. View

Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D . Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2005; 364(1-2):82-90. DOI: 10.1016/j.cca.2005.06.013. View

Reygaerts T, Mitrovic S, Fautrel B, Gossec L . Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis. Joint Bone Spine. 2018; 85(4):405-410. DOI: 10.1016/j.jbspin.2018.01.011. View

Garrett S, Jenkinson T, Kennedy L, Whitelock H, Gaisford P, Calin A . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21(12):2286-91. View

Smolen J, Breedveld F, Burmester G, Bykerk V, Dougados M, Emery P . Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015; 75(1):3-15. PMC: 4717393. DOI: 10.1136/annrheumdis-2015-207524. View

Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A . British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009; 48(4):436-9. DOI: 10.1093/rheumatology/ken450a. View

Dowty M, Lin T, Jesson M, Hegen M, Martin D, Katkade V . Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019; 7(6):e00537. PMC: 6857076. DOI: 10.1002/prp2.537. View

Strand V, Kremer J, Gruben D, Krishnaswami S, Zwillich S, Wallenstein G . Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2016; 69(4):592-598. PMC: 5413813. DOI: 10.1002/acr.23004. View

McInnes I, Ostor A, Mease P, Tillett W, Baraliakos X, De Vlam K . Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open. 2022; 8(1). PMC: 8948377. DOI: 10.1136/rmdopen-2021-002049. View

10.

Bingham 3rd C, Walker D, Nash P, Lee S, Ye L, Hu H . The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. Arthritis Res Ther. 2022; 24(1):11. PMC: 8722138. DOI: 10.1186/s13075-021-02677-7. View

11.

Holdren M, Schieir O, Bartlett S, Bessette L, Boire G, Hazlewood G . Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort. Arthritis Rheumatol. 2020; 73(1):53-60. DOI: 10.1002/art.41499. View

12.

van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63(5):508-16. PMC: 1755008. DOI: 10.1136/ard.2003.013052. View

13.

Druce K, Basu N . Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019; 58(Suppl 5):v29-v34. PMC: 6827266. DOI: 10.1093/rheumatology/kez346. View

14.

Almeida C, Choy E, Hewlett S, Kirwan J, Cramp F, Chalder T . Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016; (6):CD008334. PMC: 7175833. DOI: 10.1002/14651858.CD008334.pub2. View

15.

Deepak H, Prince S, Deshpande P . Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis. Indian J Pharmacol. 2022; 54(3):183-193. PMC: 9396682. DOI: 10.4103/ijp.ijp_1089_20. View

16.

Korte S, Straub R . Fatigue in inflammatory rheumatic disorders: pathophysiological mechanisms. Rheumatology (Oxford). 2019; 58(Suppl 5):v35-v50. PMC: 6827268. DOI: 10.1093/rheumatology/kez413. View

17.

van der Heijde D, Deodhar A, Maksymowych W, Sieper J, Van den Bosch F, Kim T . Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open. 2022; 8(2). PMC: 9335045. DOI: 10.1136/rmdopen-2022-002280. View

18.

Husted J, Gladman D, Farewell V, Cook R . Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001; 45(2):151-8. DOI: 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T. View

19.

Jansen J, Buckley F, Dejonckheere F, Ogale S . Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network.... Health Qual Life Outcomes. 2014; 12:102. PMC: 4101713. DOI: 10.1186/1477-7525-12-102. View

20.

Huarte E, Peel M, Verbist K, Fay B, Bassett R, Albeituni S . Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Front Pharmacol. 2021; 12:650295. PMC: 8107823. DOI: 10.3389/fphar.2021.650295. View